MC2 Therapeutics gets option riqhts to Regranion candidate

25 September 2023

Privately-held Danish company MC2 Therapeutics has acquired option rights from US dermatology firm Regranion to exclusively license the latter’s RGRN-305 for the treatment of all human diseases, including oral treatment of hidradenitis suppurative (HS) globally, excluding the greater China region.

RGRN-305 is an orally administered new chemical entity in preparation for clinical Phase IIb. Under the agreement,

The deal terms provide for Regranion to receive an undisclosed upfront option payment with additional development and sales milestones as well as royalties, once MC2 Therapeutics exercises its option.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK